152 related articles for article (PubMed ID: 38187532)
1. NOS2 and COX2 Provide Key Spatial Targets that Determine Outcome in ER- Breast Cancer.
Ridnour LA; Heinz WF; Cheng RY; Wink AL; Kedei N; Pore M; Imtiaz F; Femino EL; Gonzalez AL; Coutinho L; Butcher D; Edmondson EF; Rangel MC; Kinders RJ; Lipkowitz S; Wong ST; Anderson SK; McVicar DW; Li X; Glynn SA; Billiar TR; Chang JC; Hewitt SM; Ambs S; Lockett SJ; Wink DA
bioRxiv; 2023 Dec; ():. PubMed ID: 38187532
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma is quintessential for NOS2 and COX2 expression in ER
Cheng RYS; Ridnour LA; Wink AL; Gonzalez AL; Femino EL; Rittscher H; Somasundaram V; Heinz WF; Coutinho L; Rangel MC; Edmondson EF; Butcher D; Kinders RJ; Li X; Wong STC; McVicar DW; Anderson SK; Pore M; Hewitt SM; Billiar TR; Glynn SA; Chang JC; Lockett SJ; Ambs S; Wink DA
Cell Death Dis; 2023 May; 14(5):319. PubMed ID: 37169743
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma is Quintessential for NOS2 and COX2 Expression in ER
Cheng RY; Ridnour LA; Wink AL; Gonzalez AL; Femino EL; Rittscher H; Somasundarum V; Heinz WF; Coutinho L; Cristina Rangel M; Edmondson EF; Butcher D; Kinders RJ; Li X; Wong STC; McVicar DW; Anderson SK; Pore M; Hewitt SM; Billiar TR; Glynn S; Chang JC; Lockett SJ; Ambs S; Wink DA
bioRxiv; 2023 Apr; ():. PubMed ID: 37066331
[TBL] [Abstract][Full Text] [Related]
4. Spatial analysis of NOS2 and COX2 interaction with T-effector cells reveals immunosuppressive landscapes associated with poor outcome in ER- breast cancer patients.
Ridnour LA; Cheng RYS; Heinz WF; Pore M; Gonzalez AL; Femino EL; Moffat R; Wink AL; Imtiaz F; Coutinho L; Butcher D; Edmondson EF; Rangel MC; Wong STC; Lipkowitz S; Glynn S; Vitek MP; McVicar DW; Li X; Anderson SK; Paolocci N; Hewitt SM; Ambs S; Billiar TR; Chang JC; Lockett SJ; Wink DA
bioRxiv; 2023 Dec; ():. PubMed ID: 38187660
[TBL] [Abstract][Full Text] [Related]
5. Systemic Nos2 Depletion and Cox inhibition limits TNBC disease progression and alters lymphoid cell spatial orientation and density.
Somasundaram V; Ridnour LA; Cheng RY; Walke AJ; Kedei N; Bhattacharyya DD; Wink AL; Edmondson EF; Butcher D; Warner AC; Dorsey TH; Scheiblin DA; Heinz W; Bryant RJ; Kinders RJ; Lipkowitz S; Wong ST; Pore M; Hewitt SM; McVicar DW; Anderson SK; Chang J; Glynn SA; Ambs S; Lockett SJ; Wink DA
Redox Biol; 2022 Dec; 58():102529. PubMed ID: 36375380
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer.
Basudhar D; Glynn SA; Greer M; Somasundaram V; No JH; Scheiblin DA; Garrido P; Heinz WF; Ryan AE; Weiss JM; Cheng RYS; Ridnour LA; Lockett SJ; McVicar DW; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):13030-13035. PubMed ID: 29087320
[TBL] [Abstract][Full Text] [Related]
7. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer.
Switzer CH; Cheng RY; Ridnour LA; Glynn SA; Ambs S; Wink DA
Breast Cancer Res; 2012 Sep; 14(5):R125. PubMed ID: 22971289
[TBL] [Abstract][Full Text] [Related]
8. Inducible nitric oxide synthase-derived extracellular nitric oxide flux regulates proinflammatory responses at the single cell level.
Somasundaram V; Gilmore AC; Basudhar D; Palmieri EM; Scheiblin DA; Heinz WF; Cheng RYS; Ridnour LA; Altan-Bonnet G; Lockett SJ; McVicar DW; Wink DA
Redox Biol; 2020 Jan; 28():101354. PubMed ID: 31683257
[TBL] [Abstract][Full Text] [Related]
9. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.
Glynn SA; Boersma BJ; Dorsey TH; Yi M; Yfantis HG; Ridnour LA; Martin DN; Switzer CH; Hudson RS; Wink DA; Lee DH; Stephens RM; Ambs S
J Clin Invest; 2010 Nov; 120(11):3843-54. PubMed ID: 20978357
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression.
Heinecke JL; Ridnour LA; Cheng RY; Switzer CH; Lizardo MM; Khanna C; Glynn SA; Hussain SP; Young HA; Ambs S; Wink DA
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6323-8. PubMed ID: 24733928
[TBL] [Abstract][Full Text] [Related]
11. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8
Wu Q; Liu Z; Gao Z; Luo Y; Li F; Yang C; Wang T; Meng X; Chen H; Li J; Kong Y; Dong C; Sun S; Chen C
Theranostics; 2023; 13(4):1381-1400. PubMed ID: 36923542
[No Abstract] [Full Text] [Related]
12. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham M; Lucas PC; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
bioRxiv; 2023 Aug; ():. PubMed ID: 37662409
[TBL] [Abstract][Full Text] [Related]
14. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.
Karavitis J; Hix LM; Shi YH; Schultz RF; Khazaie K; Zhang M
PLoS One; 2012; 7(9):e46342. PubMed ID: 23029485
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib enhances neuronal survival in vitro via NF-κB-mediated signaling and expression of cyclooxygenase-2 and inducible nitric oxide synthase.
Sanchez A; Tripathy D; Yin X; Luo J; Martinez JM; Grammas P
J Neuroinflammation; 2013 Jul; 10():93. PubMed ID: 23880112
[TBL] [Abstract][Full Text] [Related]
16. NOS2 as an Emergent Player in Progression of Cancer.
Thomas DD; Wink DA
Antioxid Redox Signal; 2017 Jun; 26(17):963-965. PubMed ID: 28506076
[TBL] [Abstract][Full Text] [Related]
17. S-Nitrosation Mediates Multiple Pathways That Lead to Tumor Progression in Estrogen Receptor-Negative Breast Cancer.
Switzer CH; Ridnour LA; Cheng R; Heinecke J; Burke A; Glynn S; Ambs S; Wink DA
For Immunopathol Dis Therap; 2012; 3(2):117-124. PubMed ID: 23543871
[TBL] [Abstract][Full Text] [Related]
18. Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry.
Soliman H; Rawal B; Fulp J; Lee JH; Lopez A; Bui MM; Khalil F; Antonia S; Yfantis HG; Lee DH; Dorsey TH; Ambs S
Cancer Immunol Immunother; 2013 May; 62(5):829-37. PubMed ID: 23344392
[TBL] [Abstract][Full Text] [Related]
19. The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients.
López-Janeiro Á; Villalba-Esparza M; Brizzi ME; Jiménez-Sánchez D; Ruz-Caracuel I; Kadioglu E; Masetto I; Goubert V; Garcia-Ros D; Melero I; Peláez-García A; Hardisson D; de Andrea CE
J Pathol; 2022 Dec; 258(4):426-436. PubMed ID: 36169332
[TBL] [Abstract][Full Text] [Related]
20. Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer.
Ambs S; Glynn SA
Cell Cycle; 2011 Feb; 10(4):619-24. PubMed ID: 21293193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
